Delivery Order SPE2DB20D1109-SPE2DB25FP03J
- Not listed
- The Defense Logistics Agency awarded a $5,220.55 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 19, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a $41,133.58 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This is a firm fixed price, non-set-aside contract with a completion date of June 3, 2025, and performance executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, valued at $31,332.93. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a contract ceiling value of $18,321.85. This non-set-aside, competitively awarded delivery order reflects firm fixed pricing and is scheduled for completion by April 25, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml quantities, valued at $2,424.16. This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and carries no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, valued at $13,414.74. The contract utilizes a firm fixed price structure with no set-aside designation, indicating open competition. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026,...
- The Defense Logistics Agency awarded a $2,193.31 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) vials. This is a firm fixed-price, competitively awarded contract with a completion date of July 23, 2025, and no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare...
- The Defense Logistics Agency awarded a $46,386.40 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be fulfilled at the vendor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $10,214.25 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a completion date of June 2, 2025. The contract utilizes firm fixed price terms and carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,883.86 delivery order to AmerisourceBergen Drug Corp for Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials on May 27, 2025, with an ultimate completion date of May 28, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP03JDelivery Order
The Defense Logistics Agency awarded a $38,437.96 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with completion scheduled for May 9, 2025. The contract was not set aside and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal healthcare vendor serving military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs worldwide. As a diabetes management medication, Ozempic is consistent with AmerisourceBergen Drug Corp's extensive portfolio of specialty medications and brand-name pharmaceuticals delivered under the firm's federal contract awards across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $38.4k | 5/8/25 |